Sen. Bernie Sanders. (Photo: Rick Koppstein/ALM Media)
Congressional scrutiny of drug prices continued to heat up on Thursday, with three pharmaceutical executives taking the hot seat before a Senate panel. The CEOs of Merck, Bristol Myers Squibb and Johnson & Johnson faced a barrage of questions from members of the Health, Education, Labor and Pensions committee.
"The overwhelming beneficiary of high drug prices in America is the pharmaceutical industry," committee Chair Bernie Sanders, I-Vt., said. "The United States government does not regulate drug companies. With a few exceptions, the drug companies regulate the United States government."
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
